Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.

Role of Cholinergic Signaling in Alzheimer’s Disease

Open access
Chen, Zhi-Ru, Huang, Jia-Bao, Yang, Shu-Long, Hong, Fen-Fang · 2022 · Molecules

Abstract

Acetylcholine, a neurotransmitter secreted by cholinergic neurons, is involved in signal transduction related to memory and learning ability. Alzheimer’s disease (AD), a progressive and commonly diagnosed neurodegenerative disease, is characterized by memory and cognitive decline and behavioral disorders. The pathogenesis of AD is complex and remains unclear, being affected by various factors. The cholinergic hypothesis is the earliest theory about the pathogenesis of AD. Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD. In addition, abnormal central cholinergic changes can also induce abnormal phosphorylation of ttau protein, nerve cell inflammation, cell apoptosis, and other pathological phenomena, but the exact mechanism of action is still unclear. Due to the complex and unclear pathogenesis, effective methods to prevent and treat AD are unavailable, and research to explore novel therapeutic drugs is various and active in the world. This review summaries the role of cholinergic signaling and the correlation between the cholinergic signaling pathway with other risk factors in AD and provides the latest research about the efficient therapeutic drugs and treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules27061816

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic diagram of choline neurotransmission. ACh is synthesized by choline acetylcholine transferase (ChAT) from the cytoplasm of cholinergic presynaptic neurons by acetyl-coA and choline acetylcholine transferase. It is then transferred to synaptic vesicular follicles via vesicular acetylcholine transporter (VAChT). Depolarization of presynaptic neurons promotes extracellular secretion of ACh, which can then bind to nicotine or muscarinic receptors, leading to stimulatory or inhibitory responses. AChE rapidly hydrolyzes acetylcholine at the synaptic cleft, releasing acetate and choline, which are reabsorbed by the high-affinity choline transporter (CHT1) into presynaptic cholinergic neurons.
Figure 1 Schematic diagram of choline neurotransmission. ACh is synthesized by choline acetylcholine transferase (ChAT) from the cytoplasm of cholinergic presynaptic neurons by acetyl-coA and choline acetylcholine transferase. It is then transferred to synaptic vesicular follicles via vesicular acetylcholine transporter (VAChT). Depolarization of presynaptic neurons promotes extracellular secretion of ACh, which can then bind to nicotine or muscarinic receptors, leading to stimulatory or inhibitory responses. AChE rapidly hydrolyzes acetylcholine at the synaptic cleft, releasing acetate and choline, which are reabsorbed by the high-affinity choline transporter (CHT1) into presynaptic cholinergic neurons.CC BY · PubMed Central
Figure 2 Schematic diagram of AChEI. ACh released from the presynaptic membrane into the synaptic cleft is normally rapidly hydrolyzed by AChE into choline. Choline is re-ingested by the presynaptic neuron to synthesize new ACh. People with AD have deficiency of ACh, and the levels of ACh in their brains are much lower than in normal people. AChEIs can inhibit the activity of AChE and thus block the hydrolysis of ACh, which can increase the concentration of ACh in the synaptic clefts and prolong the duration of ACh action in order to alleviate the cognitive impairment of AD patients. A, B, C, D, E refer to step A, B, C, D, E, which are the processes by which ACh is synthesized and metabolized in the body.
Figure 2 Schematic diagram of AChEI. ACh released from the presynaptic membrane into the synaptic cleft is normally rapidly hydrolyzed by AChE into choline. Choline is re-ingested by the presynaptic neuron to synthesize new ACh. People with AD have deficiency of ACh, and the levels of ACh in their brains are much lower than in normal people. AChEIs can inhibit the activity of AChE and thus block the hydrolysis of ACh, which can increase the concentration of ACh in the synaptic clefts and prolong the duration of ACh action in order to alleviate the cognitive impairment of AD patients. A, B, C, D, E refer to step A, B, C, D, E, which are the processes by which ACh is synthesized and metabolized in the body.CC BY · PubMed Central
Figure 3 Some drugs related with the treatment of AD.
Figure 3 Some drugs related with the treatment of AD.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 141 references

Research works printed but not linked: 1

  1. Yu, 2019, Protective roles of isoastilbin against Alzheimer’s disease via Nrf2mediated antioxidation and antiapoptosis, Int. J. Mol. Med., 43, 1406

Cited by

See all 1,000

Metadata

Authors
Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F.
Affiliations
  • Nanchang University (CN)
  • Experimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China
Corresponding author
  • Yang, Shu-Long
  • Hong, Fen-Fang
Venue
Molecules
Publisher
MDPI AG
Published
2022-03-10
Volume
27
Issue
6
Pages
1816
ISSN
1420-3049 (ISSN-L)
OpenAlex
W4220945110
Cited by
922
References
141
Citations by year
2026: 256 · 2025: 347 · 2024: 202 · 2023: 87 · 2022: 29
FWCI
22.89
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (82060661, 81660751, 81660151)
  • Jiangxi Provincial Natural Science Foundation of China (20212BAB206092)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, cholinergic neurotransmission, acetylcholine, cholinergic hypothesis, cognitive decline, tau phosphorylation, neuroinflammation, apoptosis, Alzheimer's disease pathogenesis, Alzheimer's disease therapeutics
MeSH terms
Acetylcholine, Alzheimer Disease, Humans, Signal Transduction, Cholinergic Agents, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Cholinergic Signaling in Alzheimer’s Disease. https://app.cochat.ai/papers/10.3390/molecules27061816
The paper
Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F. (2022). Role of Cholinergic Signaling in Alzheimer’s Disease. Molecules. https://doi.org/10.3390/molecules27061816

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.